Vaccines for use in treating various diseases and disorders

Abstract

Various diseases and disorders associated with cellular senescence may be treated by immunizing a subject in need thereof against AGE-modified proteins or peptides of a cell. Immunizing a subject includes administering a vaccine that comprises an AGE antigen. Vaccines against AGE-modified proteins or peptides contain an AGE antigen, an adjuvant, optional preservatives and optional excipients.

What is claimed is: 
     
         1 . A method of treating or preventing a disease or disorder associated with cellular senescence, comprising immunizing a subject in need thereof against AGE-modified proteins or peptides of a cell,
 wherein the disease or disorder is selected from the group consisting of sarcopenia, inflammation, the onset of cataracts, the onset of loss of adipose tissue, the onset of lordokyphosis, auto-immune disorders, and neurodegenerative disorders.   
     
     
         2 . A method of treating a subject with a disease or disorder associated with cellular senescence, comprising:
 administering a first vaccine comprising a first AGE antigen; and   administering a second vaccine comprising a second AGE antigen;   wherein the second AGE antigen is different from the first AGE antigen and   the disease or disorder associated with cellular senescence does not comprise sarcopenia.   
     
     
         3 . (canceled) 
     
     
         4 . The method of  claim 1 , wherein the immunizing comprises administering a vaccine comprising an AGE antigen. 
     
     
         5 . The method of  claim 4 , wherein the vaccine comprises
 (a) the AGE antigen,   (b) an adjuvant,   (c) optionally, a preservative, and   (d) optionally, an excipient.   
     
     
         6 . The method of  claim 1 , wherein the subject is selected from the group consisting of humans, goats, sheep, cows, horses, dogs and cats. 
     
     
         7 . The method of  claim 6 , wherein the subject is a human. 
     
     
         8 . The method of  claim 4 , wherein the vaccine is administered in an amount effective to cause the immune system to produce antibodies to cells having AGE-modified proteins or peptides. 
     
     
         9 . The method of  claim 1 , wherein the subject does not have diabetes. 
     
     
         10 . The method of  claim 4 , wherein the AGE antigen comprises, an AGE-modified protein or peptide selected from the group consisting of AGE-RNAse, AGE-human hemoglobin, AGE-human serum albumin, AGE-low density lipoprotein, AGE-collagen IV, AGE-antithrombin III, AGE-calmodulin, AGE-insulin, AGE-ceruloplasmin, AGE-collagen, AGE-cathepsin B, AGE-albumin, AGE-crystallin, AGE-plasminogen activator, AGE-endothelial plasma membrane protein, AGE-aldehyde reductase, AGE-transferrin, AGE-fibrin, AGE-copper/zinc SOD, AGE-apo B, AGE-fibronectin, AGE-pancreatic ribose, AGE-apo A-I and II, AGE-hemoglobin, AGE-Na + /K + -ATPase, AGE-plasminogen, AGE-myelin, AGE-lysozyme, AGE-immunoglobulin, AGE-red cell Glu transport protein, AGE-β-N-acetyl hexokinase, AGE-apo E, AGE-red cell membrane protein, AGE-aldose reductase, AGE-ferritin, AGE-red cell spectrin, AGE-alcohol dehydrogenase, AGE-haptoglobin, AGE-tubulin, AGE-thyroid hormone, AGE-fibrinogen, AGE-β 2 -microglobulin, AGE-sorbitol dehydrogenase, AGE-ai-antitrypsin, AGE-carbonate dehydratase, AGE-hexokinase, AGE-apo C-I, AGE-keyhole limpet hemocyanin (AGE-KLH) and mixtures thereof. 
     
     
         11 . The method of  claim 4 , wherein the AGE antigen comprises at least one protein or peptide that exhibits AGE modifications selected from the group consisting of carboxymethyllysine, carboxyethyllysine, pentosidine, pyrraline, FFI, AFGP, and ALI. 
     
     
         12 . The method of  claim 11 , wherein the AGE antigen comprises a carboxymethyllysine-modified protein or peptide. 
     
     
         13 . The method of  claim 4 , wherein
 the vaccine is sterile, and   the vaccine is in unit dosage form.   
     
     
         14 . The method of  claim 4 , wherein
 the vaccine is sterile, and   the vaccine is in multidosage form.   
     
     
         15 - 35 . (canceled) 
     
     
         36 . The method of  claim 1 , further comprising testing the subject to determine if the disease or disorder associated with cellular senescence has been ameliorated, and
 repeating the immunizing, if necessary.   
     
     
         37 . (canceled) 
     
     
         38 . (canceled) 
     
     
         39 . A method of treating or preventing atherosclerosis associated with cellular senescence, comprising immunizing a subject in need thereof against AGE-modified proteins or peptides of a cell,
 wherein the immunizing comprises administering a vaccine comprising an AGE antigen, and   the AGE antigen is not AGE-low density lipoprotein.   
     
     
         40 . The method of  claim 39 , wherein the AGE antigen comprises an AGE-modified protein or peptide selected from the group consisting of AGE-RNAse, AGE-human human hemoglobin, AGE-human serum albumin, AGE-collagen IV, AGE-antithrombin III, AGE-calmodulin, AGE-insulin, AGE-ceruloplasmin, AGE-collagen, AGE-cathepsin B, AGE-albumin, AGE-crystallin, AGE-plasminogen activator, AGE-endothelial plasma membrane protein, AGE-aldehyde reductase, AGE-transferrin, AGE-fibrin, AGE-copper/zinc SOD, AGE-apo B, AGE-fibronectin, AGE-pancreatic ribose, AGE-apo A-I and II, AGE-hemoglobin, AGE-Na + /K + -ATPase, AGE-plasminogen, AGE-myelin, AGE-lysozyme, AGE-immunoglobulin, AGE-red cell Glu transport protein, AGE-β-N-acetyl hexokinase, AGE-apo E, AGE-red cell membrane protein, AGE-aldose reductase, AGE-ferritin, AGE-red cell spectrin, AGE-alcohol dehydrogenase, AGE-haptoglobin, AGE-tubulin, AGE-thyroid hormone, AGE-fibrinogen, AGE-β 2 -microglobulin, AGE-sorbitol dehydrogenase, AGE-α 1 -antitrypsin, AGE-carbonate dehydratase, AGE-hexokinase, AGE-apo C-l, AGE-keyhole limpet hemocyanin (AGE-KLH) and mixtures thereof. 
     
     
         41 . The method of  claim 39 , wherein the AGE antigen comprises a carboxymethyllysine-modified protein or peptide. 
     
     
         42 . The method of  claim 39 , further comprising testing the subject to determine if the atherosclerosis associated with cellular senescence has been ameliorated, and
 repeating the immunizing, if necessary.   
     
     
         43 . The method of  claim 2 , wherein the first AGE antigen and the second AGE antigen each independently comprises an AGE-modified protein or peptide selected from the group consisting of AGE-RNAse, AGE-human hemoglobin, AGE-human serum albumin, AGE-low density lipoprotein, AGE-collagen IV, AGE-antithrombin III, AGE-calmodulin, AGE-insulin, AGE-ceruloplasmin, AGE-collagen, AGE-cathepsin B, AGE-albumin, AGE-crystallin, AGE-plasminogen activator, AGE-endothelial plasma membrane protein, AGE-aldehyde reductase, AGE-transferrin, AGE-fibrin, AGE-copper/zinc SOD, AGE-apo B, AGE-fibronectin, AGE-pancreatic ribose, AGE-apo A-I and II, AGE-hemoglobin, AGE-Na + K + -ATPase, AGE-plasminogen, AGE-myelin, AGE-lysozyme, AGE-immunoglobulin, AGE-red cell Glu transport protein, AGE-6-N-acetyl hexokinase, AGE-apo E, AGE-red cell membrane protein, AGE-aldose reductase, AGE-ferritin, AGE-red cell spectrin, AGE-alcohol dehydrogenase, AGE-haptoglobin, AGE-tubulin, AGE-thyroid hormone, AGE-fibrinogen, AGE-β 2 -microglobulin, AGE-sorbitol dehydrogenase, AGE-ai-antitrypsin, AGE-carbonate dehydratase, AGE-hexokinase, AGE-apo C-I, AGE-keyhole limpet hemocyanin (AGE-KLH) and mixtures thereof. 
     
     
         44 . The method of  claim 2 , wherein the first AGE antigen comprises a carboxymethyllysine-modified protein or peptide.